Caratol E Capsule | Publications of Caratol E Capsule

Better Repigmentation with Combination Therapy of Topical Tolenorm and Caratol E

Vitiligo being an autoimmune disorder requires multiple treatment approach.
In this study, 40 patients with various types of Vitiligo were treated with combined therapy of topical Tolenorm and Caratol e.
The duration of the treatment was 50 weeks.
By the end of the study period, 90% repigmentation, which was also uniform in nature, was obtained in all the cases.

Increased % of repigmentation with combination therapy of topical Tolenorm and Caratol e

Affected Areas	Face, Neck, Chest and Hands (Extensive)		Waist, Buttocks and Legs (Extensive)
No. of Weeks	% of Repigmentation	No. of Patients (out of 20)	% of Repigmentation	No. of Patients (out of 20)
12	40	7	40	1
30	50	8	50	1
52	60	9	60	2
64	70	10	70	2

Study findings

Co-effect of Caratol e along with the application of topical Tolenorm was confirmed to be better and more effective in management of Vitiligo.

Increased Repigmentation in Punch Graft Method along with combination Therapy

In another study by punch graft method, 4 localized vitiligo patients were selected.
After 6days of grafting, 2 of them were treated with combination therapy and other 2 patients were treated with topical Tolenorm.
The first group showed faster and better repigmentation than the second group.

Punch Graft study

Site of grafted area	Hand with Combination therapy (No. of patients- 2)	Hand without Combination therapy (No. of patients- 2)
No. of Weeks	% of Repigmentation	% of Repigmentation
10	40	10
14	60	20
22	80	30
35	90	40

Combination therapy was confirmed to be more effective than topical application.

Pretreatment with Caratol E Significantly Induces Antibody Production

To treat an autoimmune disorder, an effective immune modulator is required which will modulate the activity of immune cells and also protect them.
In this study, one group test mice was treated with Caratol e and other group was left as untreated.
After 30 days of immunization, in the treated group antibody production was found to be significantly high than that in the untreated group.

Caratol e when used as a pretreatment, induces antibody production

	Antibody production(IU/ml)
Test mice pretreated with Caratol e	200
Control	14

Study findings

This study shows the effectiveness of Caratol e as an immune modulator which can significantly improve the rate of antibody production when used as a pretreatment.

Request a call